Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas

Journal of Clinical Neuroscience

Volumn 17, Issue 7, 2010, Pages 842-848

  Clavreul, Anne ^a,b,c   Piard, Nicole ^d   Tanguy, Jean Yves ^a   Gamelin, Eric ^e   Rousselet, Marie Christine ^a   Leynia, Pierre ^e   Menei, Philippe ^a,b,c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ D'ANGERS   (France)

^d ETABLISSEMENT FRANÇAIS DU SANG   (France)

^e CENTRE PAUL PAPIN   (France)

Author keywords

GM CSF; Immunotherapy; Malignant glioma; Vaccination

Indexed keywords

CARMUSTINE; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LOMUSTINE; PROCARBAZINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STEROID; TEMOZOLOMIDE; TOPOTECAN; TUMOR CELL VACCINE; VINCRISTINE;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; ASTROCYTOMA; AUTOIMMUNITY; BLOOD PRESSURE; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CYANOSIS; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL; FEMALE; GLIOBLASTOMA; HEMATOMA; HEMIPLEGIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OLIGODENDROGLIOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SHIVERING; SIDE EFFECT; TREATMENT RESPONSE; TUMOR CELL CULTURE; VOMITING;

ADULT; AGED; BRAIN NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; FEMALE; GLIOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INFUSION PUMPS, IMPLANTABLE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 77952548405     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2009.11.017     Document Type: Article

References (35)

1. Westphal M., Hilt D.C., Bortey E., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5 (2003) 79-88
2. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
3. Okada H., Kohanbash G., Zhu X., et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol 29 (2009) 1-42
4. Yamanaka R. Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg Rev 32 (2009) 265-273 [discussion 273]
5. Chang D.Z., Lomazow W., Joy Somberg C., et al. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 9 (2004) 207-215
6. Plautz G.E., Barnett G.H., Miller D.W., et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 89 (1998) 42-51
7. Plautz G.E., Miller D.W., Barnett G.H., et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6 (2000) 2209-2218
8. Lefranc F., Cool V., Velu T., et al. Granulocyte macrophage-colony stimulating factor gene transfer to induce a protective anti-tumoral immune response against the 9L rat gliosarcoma model. Int J Oncol 20 (2002) 1077-1085
9. Wallenfriedman M.A., Conrad J.A., DelaBarre L., et al. Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. J Neurosurg 90 (1999) 1064-1071
10. Yu J.S., Burwick J.A., Dranoff G., et al. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 8 (1997) 1065-1072
11. Herrlinger U., Kramm C.M., Johnston K.M., et al. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 4 (1997) 345-352
12. Sloan A.E., Dansey R., Zamorano L., et al. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor, adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 9 (2000) e9
13. Ward J.E., and McNeel D.G. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther 7 (2007) 1893-1902
14. Parney I.F., Chang L.J., Farr-Jones M.A., et al. Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas. J Neurooncol 78 (2006) 71-80
15. Soiffer R., Hodi F.S., Haluska F., et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21 (2003) 3343-3350
16. Luiten R.M., Kueter E.W., Mooi W., et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 23 (2005) 8978-8991
17. Borrello I., Sotomayor E.M., Cooke S., et al. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther 10 (1999) 1983-1991
18. Jean W.C., Spellman S.R., Wallenfriedman M.A., et al. Effects of combined granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and interleukin-12 based immunotherapy against intracranial glioma in the rat. J Neurooncol 66 (2004) 39-49
19. Clavreul A., Delhaye M., Jadaud E., et al. Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model. J Neurooncol 79 (2006) 9-17
20. Macdonald D.R., Cascino T.L., Schold Jr. S.C., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 (1990) 1277-1280
21. Kaplan G., Walsh G., Guido L.S., et al. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 175 (1992) 1717-1728
22. Brem H., Piantadosi S., Burger P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345 (1995) 1008-1012
23. De Vleeschouwer S., Fieuws S., Rutkowski S., et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14 (2008) 3098-3104
24. Kikuchi T., Akasaki Y., Irie M., et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50 (2001) 337-344
25. Schneider T., Gerhards R., Kirches E., et al. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol 53 (2001) 39-46
26. Clavreul A., Jean I., Preisser L., et al. Human glioma cell culture: two FCS-free media could be recommended for clinical use in immunotherapy. In Vitro Cell Dev Biol Anim 45 (2009) 500-511
27. Wood G.W., Holladay F.P., Turner T., et al. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J Neurooncol 48 (2000) 113-120
28. Ishikawa E., Tsuboi K., Yamamoto T., et al. Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci 98 (2007) 1226-1233
29. Bigner D.D., Pitts O.M., and Wikstrand C.J. Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. J Neurosurg 55 (1981) 32-42
30. Fazekas F., Barkhof F., Filippi M., et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 53 (1999) 448-456
31. Yajima N., Yamanaka R., Mine T., et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11 (2005) 5900-5911
32. Izumoto S., Tsuboi A., Oka Y., et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108 (2008) 963-971
33. Stathopoulos A., Samuelson C., Milbouw G., et al. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat. Vaccine 26 (2008) 1764-1772
34. Mahaley Jr. M.S., Bigner D.D., Dudka L.F., et al. Immunobiology of primary intracranial tumors. Part 7: active immunization of patients with anaplastic human glioma cells: a pilot study. J Neurosurg 59 (1983) 201-207
35. Liau L.M., Prins R.M., Kiertscher S.M., et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11 (2005) 5515-5525